Novartis AG (NVS)

Oncology Corporate Profile

Stock Performance

86.2400
0.0800

3 Month Stock History Chart

HQ Location

180 Park Avenue
Florham Park, NJ 7932

Company Description

Novartis offers a wide range of healthcare products through its Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions. Its Pharmaceuticals division researches, develops, manufactures, distributes, and sells pharmaceuticals in therapeutic areas including oncology, hematology and many other areas.

Website: http://www.novartis.com

Brand Generic Indication
Afinitor®everolimusAfinitor® is a kinase inhibitor indicated for the treatment of:

• postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.

• adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. The safety and effectiveness of AFINITOR in the treatment of patients with carcinoid tumors have not been established.

• adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.

• adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes.

Afinitor® and Afinitor® Disperz are kinase inhibitors indicated for the treatment of:

• pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated.
Exjade®deferasiroxExjade® (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Farydak®panobinostatFarydak®, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1]
Femara®letrozoleFemara® is an aromatase inhibitor indicated for:
-Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

-Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.

-First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Gleevec®imatinib mesylateGleevec® is a kinase inhibitor indicated for the treatment of:

• Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Follow-up is limited to 5 years

• Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy

• Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. There are no controlled trials in pediatric patients demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival

• Adult patients with relapsed or refractory Philadelphia chromosome
positive acute lymphoblastic leukemia (Ph+ ALL)

• Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements

• Adult patients with aggressive systemic mastocytosis (ASM) without the
D816V c-Kit mutation or with c-Kit mutational status unknown

• Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1- PDGFR fusion kinase negative or unknown

• Adult patients with unresectable, recurrent and/or metastatic
dermatofibrosarcoma protuberans (DFSP)

Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
Kisqali®ribociclibKisqali® is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Kisqali® Femara® Co-Packribociclib tablets; letrozole tabletsKisqali® is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Femara® is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy; first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Kymriah™tisagenlecleucelKymriah™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Odomzo®sonidegibOdomzo® (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy
Rydapt®midostaurinRydapt® is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt® is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Sandostatin®octreotide acetateLong-term maintenance therapy for acromegaly and the treatment of symptoms related to carcinoid syndrome and VIPomas.
Tafinlar® + Mekinist®dabrafenib and trametinibTafinlar®, in combination with Mekinist®, is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. Limitation of Use: Tafinlar® is not indicated for the treatment of patients with wild-type BRAF melanoma. Mekinist® is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.
Tafinlar® + Mekinist®dabrafenib + trametinibTafinlar® in combination wit Mekinist® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Tasigna®nilotinibTasigna® is a kinase inhibitor indicated for:
-The treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

-The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
Zometa®zoledronic acidZometa® is a bisphosphonate indicated for the treatment of:

• Hypercalcemia of malignancy

• Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Important limitation of use: The safety and efficacy of Zometa® has not been established for use in hyperparathyroidism or non tumor-related hypercalcemia.
Zykadia®ceritinibZykadia® is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
dovitinib / TKI258multiple tyrosine kinase inhibitor1st line metastatic Renal cell carcinoma (RCC)III
LDE225smoothened antagonistBasal Cell Carcinoma (BCC)III
BKM120PI3K inhibitorBreast cancerIII
LEE011CDK4/6 inhibitorBreast cancerIII
alpelisib / BYL719PI3K® inhibitorHR+/HER2- advanced Breast cancerIII
SOM230somatostatin analogNeuroendocrine tumorIII
patupilone / EPO906epothiloneOvarian cancerIII
Afinitor® / everolimus / RAD001mTOR inhibitor1st line metastatic Breast cancerIIIAntisoma
Afinitor® / everolimus / RAD001mTOR inhibitorDiffuse large B-cell Lymphoma (DLBCL)IIIAntisoma
Afinitor® / everolimus / RAD001mTOR inhibitorNeuroendocrine tumorIIIAntisoma
Arzerra® / ofatumumabAnti-CD20 monoclonal antibodyRefractory Non-Hodgkin's Lymphoma (NHL)III
Gleevec® / imatinib mesylatemultiple tyrosine kinase inhibitorAdjuvant Gastrointestinal Stromal Tumor (GIST)III
Rydapt® / midostaurine / PKC412multikinase inhibitorAcute Myelogenous Leukemia (AML)III
Tasigna® / nilotinibmultiple tyrosine kinase inhibitor1st line metastatic Chronic Myelogenous Leukemia (CML)III
Tasigna® / nilotinibmultiple tyrosine kinase inhibitorGastrointestinal Stromal Tumors (GIST)III
Zometa® / zoledronic acidbisphosphonateBreast cancerIII
Zometa® / zoledronic acidbisphosphonateMultiple MyelomaIII
patupilone / EPO906epothilone1st line metastatic Hepatocellular carcinoma (HCC)II
LDK378ALK inhibitor2nd line ALK+ metastatic Non Small Cell Lung Cancer (NSCLC)II
panobinostat / LBH589pan-DAC inhibitor2nd line metastatic Hodgkin's LymphomaII
tisagenlecleucel-T / CTL019CD19-targeted chimeric antigen receptor T-cell immunotherapyAcute Lymphocytic Leukemia (ALL)II
patupilone / EPO906epothiloneBrain MetastasesII
LCL161IAP inhibitorBreast cancerII
panobinostat / LBH589pan-DAC inhibitorCutaneous T-cell Lymphoma (CTCL)II
BGJ398pim-1 inhibitorGlioblastoma Multiforme (GBM)II
LDE225smoothened antagonistMedulloblastomaII
SOM230somatostatin analogNeuroendocrine tumorII
AUY922Hsp90 inhibitorNon Small Cell Lung Cancer (NSCLC)II
capmatinib / INC280c-Met kinase inhibitorNon Small Cell Lung Cancer (NSCLC)II
patupilone / EPO906epothiloneVarious cancer typesII
BGJ398FGF-R kinase inhibitorVarious cancer typesII
Afinitor® / everolimus / RAD001mTOR inhibitorBrain cancerIIAntisoma
Afinitor® / everolimus / RAD001mTOR inhibitorMantle Cell Lymphoma (MCL)IIAntisoma
Afinitor® / everolimus / RAD001mTOR inhibitorVarious cancer typesIIAntisoma
Gleevec® / imatinib mesylatemultiple tyrosine kinase inhibitor1st line metastatic MelanomaII
Odomzo® / sonidegibhedgehog pathway inhibitorLeukemiaII
Odomzo® / sonidegibhedgehog pathway inhibitormedulloblastomaII
Promacta® / eltrombopagthrombopoietin receptor agonistAcute Myelogenous Leukemia (AML)II
Promacta® / eltrombopagthrombopoietin agonistChemotherapy-induced thrombocytopeniaII
asciminib / ABL001BCR-ABL inhibitor3rd line chronic myelogenous Leukemia (CML)I
AUY922Hsp90 inhibitorBreast cancerI
LFA102anti-prolactin receptor mAbBreast cancerI
ABL 001Bcr-abl tyrosine kinase inhibitorChronic Myelogenous Leukemia (CML)I
BKM120PI3K inhibitorGlioblastoma Multiforme (GBM)I
AEE788ErbB/VEGF inhibitorGlioblastoma Multiforme (GBM)I
ABL 001Bcr-abl tyrosine kinase inhibitorLeukemiaI
RAF265Raf and VEGFR kinase inhibitorMelanomaI
LGH447proto oncogene protein cMyelodysplastic Syndrome (MDS)I
EGF816EGFR TK inhibitorNon Small Cell Lung Cancer (NSCLC)I
BEZ235PI3K inhibitor (oral)Various cancer typesI
LDE225smoothened antagonistVarious cancer typesI
BGT226PI3K inhibitorVarious cancer typesI
panobinostat / LBH589pan-DAC inhibitorVarious cancer typesI
LBY135anti-DR5 monoclonal antibodyVarious cancer typesI
AUY922Hsp90 inhibitorVarious cancer typesI
dovitinib / TKI258multiple tyrosine kinase inhibitorVarious cancer typesI
BHQ880anti-DKK1 monoclonal antibodyVarious cancer typesI
lucatumumab / HCD122anti-CD40 monoclonal antibody (humanized)Various cancer typesIXoma
HDM201tumor suppressor protein p53 modulatorVarious cancer typesI
HSC835stem cell therapyVarious cancer typesI
ASB183mTOR inhibitorVarious cancer typesI
PIM447Pan-PIM inhibitorVarious cancer typesI
Tasigna® / nilotinibmultiple tyrosine kinase inhibitorAcute Lymphocytic Leukemia (ALL)I
Zykadia / certinibALK inhibitor2nd line ALK+ metastatic Non Small Cell Lung Cancer (NSCLC)Approved

View additional information on product candidates here »

Source: http://www.novartis.com

Recent News Headlines

Novartis Has A History Of Charging High Prices For Drugs In Colombia

11/2/2016 04:33 pm

(STAT/Pharmalot) Nov 1, 2016 - For the past four years, Novartis has refuted charges of unfairly pricing a key cancer treatment in Colombia. Internal company data show, though, that the drug maker had also charged much more in the Latin American nation for three other widely used medicines than in dozens of other countries.

Novartis Breast Cancer Drug Gets FDA Fast Track, Takes On Pfizer

11/1/2016 04:08 pm

(FoxNews.com/Reuters) Nov 1, 2016 - The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug.

Novartis LEE011 (ribociclib) Granted FDA Priority Review for First-line Treatment of HR+/HER2- Advanced Breast Cancer

11/1/2016 11:59 am

(Novartis) Nov 1, 2016 - Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to letrozole alone; underscores potential of LEE011 plus letrozole as a new treatment option for advanced breast cancer; may lead to faster access for US patients.

Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product

10/31/2016 03:39 pm

(Novartis) Oct 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.

Novartis Looks at Up to $5 Billion Deals in Cancer, Generics

10/26/2016 04:46 pm

(Bloomberg/Markets blog) Oct 25, 2016 - Novartis AG, Europe’s second-biggest drugmaker by sales, said it’s looking for acquisitions that cost between $2 billion and $5 billion to bolster its position in areas including cancer and the development of copycat medicines.

Novartis CEO Sees Tougher U.S. Drug Pricing over next Three-Five Years

10/25/2016 05:36 pm

(Reuters) Oct 25, 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.

Novartis ALK+ Metastatic NSCLC Therapy Zykadia® Extends Progression-free Survival Beyond 18 Months in Phase II Study

10/10/2016 03:11 pm

(StreetInsider) Oct 9, 2016 - Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients taking Zykadia® (ceritinib) as their first ALK inhibitor (post-chemotherapy) had a median progression-free survival (PFS) of 18.4 months [95% CI: 10.9-26.3; median follow-up time of 25.9 months, as measured by blinded independent review committee (BIRC)][1].

Novartis’ Tafinlar® (dabrafenib) + Mekinist® (trametinib) Demonstrate Superior Overall Survival Benefit In Advanced Melanoma Patients At Three-Year Follow Up

10/10/2016 03:11 pm

(MarketWatch) Oct 8, 2016 – Novartis today announced data from the Phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to vemurafenib mono therapy.

Novartis Breakthrough Therapy LEE011 Plus Letrozole Demonstrates Superior Progression-Free Survival As First-Line Treatment For Hr+/HER2- advanced Breast Cancer Compared To A Standard Of Care

10/10/2016 03:10 pm

(Yahoo! Finance) Oct 8, 2016 - Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months - not reached) vs. 14.7 months (13.0 - 16.5 months); HR=0.556; p=0.00000329)[1].

Novartis Targets Breast Cancer Drug Approval to Take on Pfizer

10/10/2016 02:45 pm

(Bloomberg) Oct 8, 2016 - An experimental Novartis AG treatment for a form of advanced breast cancer slashed the risks of death and the disease progressing in a study, paving the way for the Swiss drugmaker to seek regulatory approval in the U.S. and Europe by the end of the year.

Novartis's Zykadia Gets Positive Results, Faces Roche Pressure

9/23/2016 03:52 pm

(Reuters) Sept 23, 2016 - Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug.

Novartis Announces Positive Top-Line Results From ASCEND-4, a Phase III Trial of Zykadia® In Untreated Adult ALK+ NSCLC Patients

9/23/2016 12:20 pm

(Novartis) Sept 23, 2016 - Novartis today announced top-line results from its Phase III ASCEND-4 clinical study for Zykadia® (ceritinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.

Novartis Says MS Drug Cut Risk Of Disability Advance In Study

9/19/2016 04:52 pm

(Reuters) Sept 17, 2016 - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial.

Novartis Survey Published In The Breast Journal Reveals Major Gaps In Treatment Discussions Between Metastatic Breast Cancer Patients And Doctors

9/14/2016 04:56 pm

(Novartis Oncology) Sept 14, 2016 - 89% of metastatic breast cancer patients surveyed feel it’s important to discuss a long-term treatment “roadmap” with their doctor at initial diagnosis, yet 43% report not having that conversation; patients seek comprehensive dialogue with oncologists to understand treatment options and quality of life issues throughout the course of their disease; results led to a community-endorsed personalized discussion guide to help improve communications between patients and oncologists.

Novartis Dissolves CAR-T Unit, Cutting 120 Positions

9/1/2016 04:10 pm

(Forbes) Aug 31, 2016 - Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts.

Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

9/1/2016 12:07 pm

(Bloomberg) Aug 31, 2016 - Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment.

Novartis Wins Federal OK For Biosimilar Version Of Amgen’s Enbrel

8/31/2016 04:16 pm

(Boston Globe/Associated Press) Aug 31, 2016 - US regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.

Novartis Announces Positive Phase III Results For MS Drug Siponimod

8/25/2016 04:46 pm

(Reuters) Aug 25, 2016 - Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

Penn Medicine's Carl June, MD, Receives Novartis Immunology Award for Cancer Cell Therapy Development

8/25/2016 04:19 pm

(Penn Medicine) Aug 25, 2016 - Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of Translational Research in Penn’s Abramson Cancer Center, has been awarded a 2016 Novartis Prize for Clinical Immunotherapy.

NICE Says Novartis’ And Janssen’s Cancer Drugs Are Not Cost Effective

8/18/2016 12:17 pm

(European Pharmaceutical Review) Aug 18, 2016 - In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective.

Novartis Upends Early-Stage Drug Research

8/11/2016 04:40 pm

(Forbes) Aug 11, 2016 - A few years ago, researchers at Novartis saw a disconnect between its robust cancer drug development pipeline, and the speed and efficacy by which it tested small molecules on real tumors. So it innovated the way it conducts early-stage research.

Novartis Execs In Korea Are Indicted For Bribing Doctors

8/10/2016 04:19 pm

(STAT) Aug 9, 2016 - Six former and current Novartis executives at its Korean unit were indicted Monday on charges of paying more than $2 million to doctors in return for prescribing its medicines, a company spokesman confirmed. Among those indicted was the former chief executive in the country.

Novartis Asthma Pill Shows Promise In Small Trial

8/8/2016 04:28 pm

(Reuters) Aug 6, 2016 - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.

US Breakthrough Status For Novartis’ Breast Cancer Drug

8/3/2016 03:36 pm

(PharmaTimes [UK]) Aug 3, 2016 - Novartis' experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) has picked up a Breakthrough Therapy designation in the US for the treatment of certain forms of breast cancer.

Novartis CDK4/6 Inhibitor LEE011 (ribociclib) Receives FDA Breakthrough Therapy Designation as First-line Treatment for HR+/HER2- Advanced Breast Cancer

8/3/2016 11:48 am

(Novartis) Aug 3, 2016 - Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.

Broccoli Sprout Extract May Protect Against Oral Cancer Recurrence

6/23/2016 10:05 am

(UPMC) June 23, 2016 - Potent doses of broccoli sprout extract activate a “detoxification” gene and may help prevent cancer recurrence in survivors of head and neck cancer, according to a trial by the University of Pittsburgh Cancer Institute, partner with UPMC Cancer Center, confirming preliminary results presented last year at the American Association for Cancer Research Annual Meeting.

Study Finds Surgery Can Lengthen Survival Of Metastatic Kidney Cancer Patients

6/21/2016 12:01 pm

(Dana-Farber) June 20, 2016 - Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Study Finds Patient Navigators Improve Comprehensive Cancer Screening Rates

6/21/2016 12:01 pm

(Mass General) June 20, 2016 - A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators – individuals who assist patients in receiving health care services – may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.

Novartis Aims To Nearly Triple Biosimilar Drugs On Market By 2020

6/20/2016 12:02 pm

(Reuters) June 20, 2016 - Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.

Snapshot of a Case-Based Financial Advocacy Network Workshop

6/15/2016 12:00 pm

(ACCCBuzz) June 15, 2016 - ACCC recently held its first Financial Advocacy Network (FAN) Case-Based Workshop of 2016.

Presurgery Chemotherapy May Make Advanced Ovarian Cancers Responsive to Immunotherapy

6/15/2016 11:05 am

(AACR) June 15, 2016 - Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Will CAR-T Deliver On The Promise Of Widespread Therapeutic Improvement?

6/9/2016 11:02 am

(MedCity News) June 8, 2016 - So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?

J&J Myeloma Drug, In Combo Regimen, Delays Worsening Of The Disease

6/5/2016 05:05 pm

(Reuters) June 5, 2016 - Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.

New Immune Therapy Drug Gives Bladder Cancer Patients Fresh Hope

6/5/2016 05:05 pm

(NBC News) June 5, 2016 - A newly approved drug that gives the immune system a boost helped stall the spread of tumors in patients with advanced bladder cancer, researchers reported Sunday.

U.S. FDA Staff Posts Voting Questions For Teva's Opioid Painkiller

6/4/2016 06:00 pm

(Reuters) June 3, 2016 - U.S. Food and Drug Administration staff released voting questions on Teva Pharmaceutical Industries Ltd's long-acting opioid painkiller for a panel of independent experts who will recommend to the agency whether to approve the drug.

Novartis Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-free Remission (TFR) After Stopping Tasigna®

6/4/2016 05:03 pm

(Benzinga) June 4, 2016 - Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program.

New JTCC Studies Demonstrate Clinical And Economic Value Of Genomic Profiling In Improving Care And Outcomes In Non-Small Cell Lung Cancer And Breast Cancer

6/4/2016 05:01 pm

(The Business Journals) June 4, 2016 - Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potentially substantial therapeutic benefit of genomic profiling in serious, life-threatening cancers.

Vermont Poised To Become First State To Require Pharma To Justify Pricing

5/23/2016 12:01 pm

(STAT/Pharmalot) May 19, 2016 - In less than a month, Vermont could become the first state in the country to require drug makers to justify price hikes on their medicines, a move that may prompt others to take similar action but also spark a battle with the pharmaceutical industry.

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE(R) (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer

5/19/2016 12:03 pm

(bizjournals.com) May 19, 2016 - Study to evaluate MM-151 in combination with ONIVYDE plus fluorouracil and leucovorin.

Merck KGaA, Darmstadt, Germany, and Pfizer To Present Avelumab Data In Seven Different Cancers At ASCO Annual Meeting

5/19/2016 12:02 pm

(Pfizer) May 18, 2016 - 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer; two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma; data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers; JAVELIN clinical program rapidly accelerating.

Colombia Battles World's Biggest Drugmaker Over Cancer Drug

5/18/2016 12:04 pm

(ABC News/Associated Press) May 18, 2016 - Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.

'Right to Try' Bill in Senate for Terminally Ill Patients

5/17/2016 12:00 pm

(Medscape Medical News) May 16, 2016 - A new bill introduced in the Senate is designed to increase access to experimental drugs for dying patients and circumvent the FDA.

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study

5/5/2016 11:04 am

(Yahoo! Finance) May 4, 2016 - RedHill Biopharma Ltd. today announced that the U.S. National Cancer Institute (“NCI”) has awarded the Medical University of South Carolina (“MUSC”) a $1.8 million grant to support a broad range of studies on the feasibility of targeting sphingolipid metabolism for the treatment of a variety of solid tumor cancers.

SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig)

5/5/2016 11:01 am

(Morningstar) May 4, 2016 - SELLAS Life Sciences Group today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) were presented at the plenary session of the iMig 2016 Conference, being held May 1-4, 2016, in Birmingham, UK.

New Cancer Drugs Could Treat Lethal Resistant Prostate Cancers

5/2/2016 11:01 am

(Institute of Cancer Research [UK]) May 1, 2016 - Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.

Narrow Band Imaging Can Reduce Recurrence Of Bladder Tumors

5/2/2016 11:01 am

(University of Birmingham [UK]) Apr 28, 2016 - Research into bladder tumour surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.

FDA Approval: Cabozantinib (CABOMETYX)

4/26/2016 12:00 pm

(FDA.gov) Apr 25, 2016 - On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

Next Generation ACO Model Letter of Intent Deadline Extended

4/25/2016 11:04 am

(ACCC) Apr 21, 2016 - The Centers for Medicare & Medicaid Services (CMS) announced that the deadline for submission of a Next Generation ACO Model Letter of Intent (LOI) has been extended to May 20, 2016.

Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) With Atezolizumab in the Treatment of Acute Myeloid Leukemia

4/20/2016 12:01 pm

(Astex) Apr 19, 2016 - Astex Pharmaceuticals, Inc. announced today that it has entered into a clinical collaboration with Genentech to evaluate the potential for combining Astex’s next generation hypomethylating agent, guadecitabine (SGI-110), with Genentech’s investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML).

OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016

4/20/2016 11:05 am

(Yahoo! Finance) Apr 19, 2016 - OncoSec Medical Incorporated today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse™ IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy.